Skip to main content
SpringerLink
Log in

The Promise of T Cell Immunotherapy of Cancer

  • Chapter
Book cover Advances in haemapheresis

Part of the book series: Developments in Hematology and Immunology ((DIHI,volume 25))

  • 46 Accesses

Abstract

The prospects for immunotherapy of cancer have fluctuated considerably since the beginning of this century when Paul Ehrlich first proposed that the immune system might be of prime importance in protection against tumor growth. It is now obvious that the road to successful immunotherapy of human cancer is not easy, but the potential ingredients of effective therapy have been delineated. In this short review we shall discuss the state of the art and indicate which hurdles have to be taken in order for tumor immunotherapy to establish itself firmly in clinical practise.

Part of this manuscript is based on work supported by grants from the Dutch Cancer Society and the Netherlands Organization for Scientific Research (NWO). W.M. Kast is a fellow of the Royal Dutch Academy of Sciences (KNAW).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Klein G. Tumor specific transplantation antigens: GHA Clowes memorial lecture. Cancer Res 1968;28:625–35.

    CAS  PubMed  Google Scholar 

  2. Melief CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. In: Klein G, VandeWoude G (eds). Adv Cancer Res. Orlando, FLA: Academic Press, 1991, in press.

    Google Scholar 

  3. Melief CJM, Kast WM. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms. In: Klein E (ed). Seminars in cancer biology. London: WB Saunders Co, 1991, in press.

    Google Scholar 

  4. North RJ, Awwad M, Dunn PL. T-cell-mediated tumor regression in experimental systems. In: Melchers F (ed). Progress in Immunology, Vol VII. Berlin: Springer Verlag, 1989:1097–103.

    Chapter  Google Scholar 

  5. Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Ann Rev Immunol 1989;7:601–24.

    Article  CAS  Google Scholar 

  6. Deverson EV, Gow IR, Coadwell WJ, Monaco JJ, Butcher GW, Howard JC. MHC class II region encoding proteins related to the multidrug resistance family of transmembrane transporters. Nature 1990;348: 738–40.

    Article  CAS  PubMed  Google Scholar 

  7. Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A. Sequences encoded in class II region of the MHC related to the “ABC” super- family of transporters. Nature 1990;348:741–3.

    Article  CAS  PubMed  Google Scholar 

  8. Spies T, Bresnahan M, Brahram S, et al. A gene in the human major histo-compatibility class II region controlling the class I presentation pathway. Nature 1990;348:744–7.

    Article  CAS  PubMed  Google Scholar 

  9. Monaco JJ, Cho S, Attaya M. Transport protein genes in the murine MHC: Possible implications for antigen processing. Science 1990;250: 1723–6.

    Article  CAS  PubMed  Google Scholar 

  10. Roche PA, Cresswell P. Invariant chain association with HLA DR molecules inhibits immunogenic peptide binding. Nature 1990;345:615–7.

    Article  Google Scholar 

  11. Teyton L, O’Sullivan D, Dickson PW, et al. Invariant chain distinguishes between exogenous and endogenous presentation pathways. Nature 1990; 348:39–44.

    Article  CAS  PubMed  Google Scholar 

  12. Morrison LA, Braciale VL, Braciale TJ. Antigen form influences induction and frequency of influenza-specific class I and class II MHC restricted cytolytic T lymphocytes. J Immunol 1988;141:363–8.

    CAS  PubMed  Google Scholar 

  13. Carbone F, Bevan MJ. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization. J Exp Med 1989;169:603–12.

    Article  CAS  PubMed  Google Scholar 

  14. Deres K, Schild H, Wiesmüller K-H, Jung G, Rammensee H-G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopep- tide vaccine. Nature 1989;342:561–4.

    Article  CAS  PubMed  Google Scholar 

  15. Aichele P, Hengartner H, Zinkernagel RM, Schulz M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med 1990;171:1815–20.

    Article  CAS  PubMed  Google Scholar 

  16. Schulz M, Zinkernagel RM, Hengartner H. Peptide-induced antiviral protection by cytotoxic T cells. Proc Natl Acad Sci USA 1991;88:991–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Kast WM, Roux L, Curren J, et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci USA 1991, in press.

    Google Scholar 

  18. Van Bleek G, Nathenson SG. Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature 1990;348:213–6.

    Article  PubMed  Google Scholar 

  19. Rötzschke O, Falk F, Deres K, et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990;348: 252–4.

    Article  PubMed  Google Scholar 

  20. Schumacher TNM, De Bruijn MLH, Vernie LN, et al. Peptide selection by MHC class I molecules. Nature 1991, in press.

    Google Scholar 

  21. Melief CJM, Vasmel WLE, Offringa R, et al. Immunosurveillance of virus induced tumors. In: Cold Spring Harbor Symposia on Quantitative Biology, Vol 54. Cold Spring Harbor NY: Cold Spring Harbor Laboratory Press, 1989;597–603.

    Google Scholar 

  22. Melief kCJM, Kast WM. Efficacy of cytotoxic T lymphocytes against virus-induced tumors. Cancer Cells 1990;2:116–20.

    Google Scholar 

  23. Kast WM, Offringa R, Peters PJ, et al. Eradication of Adenovirus El-induced tymors by E1A specific cytotoxic T lymphocytes. Cell 1989;59: 603–14.

    Article  CAS  PubMed  Google Scholar 

  24. Kast WM, Melief CJM. Fine specificity of cytotoxic T lymphocytes directed against Adenovirus induced tumors and peptide-MHC binding. Int J Cancer 1991, in press.

    Google Scholar 

  25. Zbar B, Rapp HJ. Immunotherapy of guinea pig cancer with BCG. Cancer Res 1974;(Suppl.)34:1532–40.

    Google Scholar 

  26. Bast RC, Bast BS, Rapp HJ. Critical review of previously reported animal studies of tumor immunotherapy with nonspecific immuno-stimulants. Ann NY Acad Sci 1976;277:60–93.

    Article  CAS  PubMed  Google Scholar 

  27. Shu S, Chou T, Sakai K. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol 1989;143:740–8.

    CAS  PubMed  Google Scholar 

  28. Boon T, van Pel A, de Plaen E. Tum-transplantation antigens, point mutations, and antigenic peptides: A model for tumor-specific transplantation antigens. Cancer Cells 1989;1:25–8.

    CAS  PubMed  Google Scholar 

  29. Mulé JJ, Yang JC, Afrenière RL, Shu S, Rosenberg SA. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high dose recombinant IL-2. J Immunol 1987;139:285–94.

    PubMed  Google Scholar 

  30. Fearon ER, pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of anti-tumor response. Cell 1990;60:397–403.

    Article  CAS  PubMed  Google Scholar 

  31. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorgenicity and in- duces protective immunity. J Exp Med 1990;172:1217–24.

    Article  CAS  PubMed  Google Scholar 

  32. Ley V, Roth C, Langlade-Demoyen P, Larssen E-L, Kourilsky P. A novel approach to the induction of specific cytolytic T cells in vivo. Res Immunol 1990;141:855–63.

    Article  CAS  PubMed  Google Scholar 

  33. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retro-viral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820–5.

    CAS  PubMed  Google Scholar 

  34. Greenberg PD, Klarnet JP, Kern DE, Cheever MA. Therapy of disseminated tumors by adoptive transfer of specifically immune T cells. Progr Exp Tumor Res 1988;32:104–27.

    CAS  PubMed  Google Scholar 

  35. Degiovanni G, Lakaye T, Herin M, Hainaut P, Boon T. Antigenic heterogeneity of a human melanoma tumor detected by autologous CTL clones. Eur J Immunol 1988;18:671–6.

    Article  CAS  PubMed  Google Scholar 

  36. Fossati G, Anichini A, Sguarcina P, Mazzocchi A, Parmiani G. Prolif-erative and/or cytotoxic activity of lymphocyte clones to autologous me- lanoma. Int J Cancer 1988;42:239–45.

    Article  CAS  PubMed  Google Scholar 

  37. Darrow TL, Slingluff CL, Seyler HF. The role of HLA class I antigens in recognition of melanoma cells by tumor specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J Immunol 1989;142:3329–35.

    CAS  PubMed  Google Scholar 

  38. Wölfel T, Klehmann EM, Müller C, Schütt KH, Meyer zum Buschenfelde KH, Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones. J Exp Med 1989;170:797–810.

    Article  PubMed  Google Scholar 

  39. Van den Eynde B, Hainaut P, Hérin M, et al. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer 1989;44:634–40.

    Article  PubMed  Google Scholar 

  40. Gervois N, Heuze F, Diez E, Jotereau F. High proliferative capacity and specific anti-autologous melanoma cytotoxicity of a human T lymphocyte clone derived from tumor-infiltrating lymphocytes. Human Immunol 1990;28:112–8.

    Article  CAS  Google Scholar 

  41. Gervois N, Heuze F, Diez E, Jotereau F. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: Cytotoxic activity and T-cell receptor rearrangement. Eur J Immunol 1990;20:825–31.

    Article  CAS  PubMed  Google Scholar 

  42. Notter M, Schirrmacher V. Tumor-specific T cell clones recognize different protein determinants of autologous human malignant melanoma cells. Int J Cancer 1990;45:834–41.

    Article  CAS  PubMed  Google Scholar 

  43. Jung S, Schluesener J. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 1991;173:273–6.

    Article  CAS  PubMed  Google Scholar 

  44. Rodriguez NR, Rowan A, Smith MEF, et al. P53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990;87:7555–9.

    Article  Google Scholar 

  45. Halevy O, Michalovitz D, Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 1990;250:113–6.

    Article  CAS  PubMed  Google Scholar 

  46. Van Denderen J, van den Plas D, Meeuwsen T, et al. Immunologic characterization of the tumor-specific bcr-abl junction in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1990;76:136–41.

    PubMed  Google Scholar 

Download references

Authors
  1. C. J. M. Melief
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. M. Kast
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Red Cross Blood Bank Groningen-Drenthe, The Netherlands

    C. Th. Smit Sibinga

  2. University Hospital Utrecht, The Netherlands

    L. Kater

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Melief, C.J.M., Kast, W.M. (1991). The Promise of T Cell Immunotherapy of Cancer. In: Sibinga, C.T.S., Kater, L. (eds) Advances in haemapheresis. Developments in Hematology and Immunology, vol 25. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3904-9_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3904-9_21

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6742-0

  • Online ISBN: 978-1-4615-3904-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation